In this study, we validated that prophylactic but not therapeutic administration of OCA exerted sufficient anti-fibrotic effects in CCl4-, BDL- and NASH-induced liver fibrosis, suggesting that the functional response of FXR to its agonists may be compromised during the process of fibrogenesis. Here, NR1H4 is linked to metabolic dysfunction-associated steatohepatitis.